Ionis Pharmaceuticals, Inc. $IONS is Privium Fund Management B.V.’s 10th Largest Position

Privium Fund Management B.V. trimmed its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 7.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 248,894 shares of the company’s stock after selling 18,700 shares during the quarter. Ionis Pharmaceuticals comprises about 2.9% of Privium Fund Management B.V.’s investment portfolio, making the stock its 10th largest holding. Privium Fund Management B.V.’s holdings in Ionis Pharmaceuticals were worth $16,283,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $25,000. Golden State Wealth Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares during the period. Mather Group LLC. purchased a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $27,000. Allworth Financial LP grew its holdings in Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after purchasing an additional 517 shares during the period. Finally, Meeder Asset Management Inc. grew its position in shares of Ionis Pharmaceuticals by 620.2% in the third quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock valued at $47,000 after purchasing an additional 614 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Activity at Ionis Pharmaceuticals

In other news, EVP Shannon L. Devers sold 44,199 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $85.08, for a total transaction of $3,760,450.92. Following the transaction, the executive vice president owned 17,494 shares in the company, valued at approximately $1,488,389.52. This trade represents a 71.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph H. Wender sold 28,000 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the completion of the sale, the director owned 36,035 shares of the company’s stock, valued at approximately $2,912,348.70. The trade was a 43.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 277,891 shares of company stock worth $21,730,823 in the last quarter. Company insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IONS shares. Stifel Nicolaus boosted their price objective on Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research note on Monday, October 6th. Needham & Company LLC raised their price target on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $89.00 price objective (up from $85.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, October 30th. Wells Fargo & Company upped their target price on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, TD Cowen restated a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.45.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $82.67 on Friday. The firm has a fifty day simple moving average of $80.25 and a 200-day simple moving average of $66.21. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The company has a market capitalization of $13.39 billion, a PE ratio of -48.92 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.15.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The company had revenue of $156.72 million for the quarter, compared to analysts’ expectations of $131.75 million. During the same period in the prior year, the company earned ($0.95) earnings per share. The firm’s revenue was up 17.2% compared to the same quarter last year. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.